Anne Langsted

Anne Langsted

Auto-generated profile, based on publicly available information

Anne Langsted

The Copenhagen General Population Study, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls Vej 73, 2730, Herlev, Denmark; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark; Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Pathology
Verified
Journal Article
Closed access
ALAnne Langsted
Anne Langsted
BNBørge G. Nordestgaard
Børge G. Nordestgaard

3 June 2024 in JACC
Verified
Journal Article
Closed access
CJCamilla Ditlev Lindhardt Johannesen
Camilla Ditlev Lindhardt Johannesen
ALAnne Langsted
Anne Langsted
BNBørge Grønne Nordestgaard
Børge Grønne Nordestgaard
MMMartin Bødtker Mortensen
Martin Bødtker Mortensen

2 August 2023 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
SHSigne E J Hansen
Signe E J Hansen
AVAnette Varbo
Anette Varbo
BNBørge G Nordestgaard
Børge G Nordestgaard
ALAnne Langsted
Anne Langsted
Background: Triglycerides are a major source of energy, while high plasma triglycerides are a risk factor for various diseases and premature death. Severely elevated plasma triglycerides are a well-established cause of acute pancreatitis with high mortality, likely due to the presence of elevated levels of chylomicrons and large very low-density lipoproteins in plasma. As markedly elevated levels of these very large lipoproteins are not generally found in mild to moderate hypertriglyceridemia, this was previously not regarded as a cause or marker of increased risk of acute pancreatitis. However, mild to moderate hypertriglyceridemia may identify individuals who at a later timepoint develop severe hypertriglyceridemia and acute pancreatitis. Content: We describe measurement of plasma triglycerides and studies on plasma triglycerides and risk of acute pancreatitis. Further, we summarize current European and American guidelines for the prevention of acute pancreatitis and, finally, the potential for future prevention of acute pancreatitis through lowering of plasma triglycerides. Summary: Recent observational and genetic studies indicate that mild to moderate hypertriglyceridemia is causally related to increased risk of acute pancreatitis, most likely as a marker of future severe hypertriglyceridemia. Current guidelines do not mention individuals with mild to moderate hypertriglyceridemia, even though newer evidence suggests an unmet medical need. Treatment could include plasma triglyceride-lowering therapy targeting the pathway for lipoprotein lipase as the main triglyceride degrading enzyme in plasma. Angiopoietin-like 3 and apolipoproteinC-III are inhibitors of lipoprotein lipase, and blocking of these 2 inhibitors is showing promising results in relation to marked triglyceride-lowering and could perhaps be used to prevent acute pancreatitis in the future.

9 July 2022 in Annals of Neurology
Verified
Journal Article
Open access
CJCamilla D. L. Johannesen
Camilla D. L. Johannesen
MMMartin B. Mortensen
Martin B. Mortensen
ALAnne Langsted
Anne Langsted
BNBørge G. Nordestgaard
Børge G. Nordestgaard
Objective: Conflicting results have been reported on the association between lipids and risk of ischemic stroke. We tested the hypothesis that the burden of ischemic stroke attributable to either elevated apolipoprotein B (apoB) or non‐high‐density lipoprotein (non‐HDL) cholesterol is higher than that attributable to elevated low‐density lipoprotein (LDL) cholesterol.Methods: We included 104,618 individuals from an ongoing cohort study, the Copenhagen General Population Study. The associations of quintiles of apoB, non‐HDL cholesterol, and LDL cholesterol with risk of ischemic stroke were estimated by Cox proportional hazards regressions with 95% confidence intervals. With 1stquintile as reference, the proportion of ischemic stroke attributable to the 2nd, 3rd, 4th, and 5thquintiles of apoB, non‐HDL cholesterol, and LDL cholesterol were estimated by population attributable fractions.Results: Higher quintiles of apoB and non‐HDL cholesterol were associated with increased risk of ischemic stroke (both trends:p < 0.0001), whereas for LDL cholesterol this association was somewhat attenuated (trend:p = 0.0005). A similar pattern was seen for population attributable fraction values. Compared to individuals in the 1stquintile, the combined proportion of ischemic stroke attributable to individuals in the 2ndto 5thquintiles was 16.3% for apoB (levels >82 mg/dL), 14.7% for non‐HDL cholesterol (>3.0 mmol/L; >117 mg/dL), and 6.8% for LDL cholesterol (>2.4 mmol/L; >94 mg/dL).Interpretation: The proportion of ischemic stroke attributable to either elevated apoB or non‐HDL cholesterol was double that attributable to elevated LDL cholesterol. ANN NEUROL 2022;92:379–389

20 May 2019 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
ALAnne Langsted
Anne Langsted
BNBørge G. Nordestgaard
Børge G. Nordestgaard

16 April 2020 in Current Opinion in Lipidology
Verified
Journal Article
Closed access
ALAnne Langsted
Anne Langsted
BNBørge G. Nordestgaard
Børge G. Nordestgaard
Purpose of review: To summarize the recent studies directly comparing LDL and lipoprotein(a) as causal factors for cardiovascular disease and mortality. Recent findings: In approximately 100,000 individuals from the Copenhagen General Population Study for risk of myocardial infarction, in observational analyses per 39 mg/dl (1 mmol/l) cholesterol increase, the hazard ratio was 1.3 (95% confidence interval: 1.2–1.3) for LDL cholesterol and 1.6 (1.4–1.9) for lipoprotein(a) cholesterol. In corresponding genetic analyses, the causal risk ratio was 2.1 (1.3–3.4) for LDL and 2.0 (1.6–2.6) for lipoprotein(a). Also, a 15 mg/dl (0.39 mmol/l) cholesterol increase was associated with a hazard ratio for cardiovascular mortality of 1.05 (1.04–1.07) for LDL cholesterol and 1.18 (1.12–1.25) for lipoprotein(a) cholesterol. Corresponding values for all-cause mortality were 1.01 (1.00–1.01) for LDL cholesterol and 1.07 (1.04–1.10) for lipoprotein(a) cholesterol. In genetic, causal analyses, the mortality increases for elevated lipoprotein(a) appeared to be through apolipoprotein(a) kringle IV-2 rather than through lipoprotein(a) levels per se. Summary: On cholesterol scales, lipoprotein(a) and LDL appeared equal as causal factors for myocardial infarction; however, lipoprotein(a) was most important for mortality. Lipoprotein(a) effects may not only be due to cholesterol content but could also be due to the structure of lipoprotein(a) resembling plasminogen.